Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 27, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - China Feihe (06186) repurchased 5.886 million shares for a total of 24.0721 million yuan, representing 0.152% of its total share capital with a year-to-date total of 13.771 million shares repurchased [1][2] - Guosheng Tang (02273) repurchased 244,400 shares for 7.1899 million yuan, with a year-to-date total of 5.5026 million shares, accounting for 2.322% of its total share capital [2] - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7710 million yuan, with a year-to-date total of 21.716 million shares, representing 0.555% of its total share capital [2] Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 711,000 shares for 5.7458 million yuan, with a year-to-date total of 2.5925 million shares, accounting for 0.620% of its total share capital [2] - Zhongxu Future (09890) repurchased 345,200 shares for 5.0690 million yuan, with a year-to-date total of 647,400 shares, representing 1.210% of its total share capital [2] - Kangchen Pharmaceutical (01681) repurchased 100,000 shares for 1.5400 million yuan, with a year-to-date total of 740,600 shares, accounting for 8.700% of its total share capital [2][3]

格隆汇10月27日丨康臣药业(01681.HK)发布公告，2025年10月27日耗资154万港元回购10万股，回购价 格每股15.4港元。 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1 - The company will repurchase 100,000 shares at a total cost of HKD 1.54 million [1] - The buyback is scheduled for October 27, 2025, suggesting a strategic long-term investment approach [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年10月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].

智通财经APP讯，康臣药业(01681)公布，2025年10月24日耗资151.8万港元回购10万股股份。 该信息由智通财经网提供 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - 康臣药业 plans to repurchase 100,000 shares at a total cost of HKD 1.518 million [1] - The buyback price is set at HKD 15.18 per share [1] - The transaction is scheduled for October 24, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年10月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | ...

Core Viewpoint - 康臣药业 has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2] Share Buyback Summary - On October 23, 康臣药业 repurchased 422,000 shares at a price range of HKD 14.740 to HKD 15.040, totaling HKD 6.2941 million [2] - The stock closed at HKD 14.980 on the same day, reflecting a decrease of 2.73% with a total trading volume of HKD 26.6429 million [2] - Since October 14, the company has conducted buybacks for 8 consecutive days, acquiring a total of 2.011 million shares for a cumulative amount of HKD 30.7041 million, during which the stock price fell by 6.38% [2] - Year-to-date, 康臣药业 has completed 26 buyback transactions, repurchasing a total of 7.206 million shares for a total expenditure of HKD 89.2351 million [2] Detailed Buyback Data - The buyback details include various dates, number of shares repurchased, highest and lowest prices, and total amounts spent, showcasing a consistent buyback strategy [3]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - 康臣药业 plans to repurchase 422,000 shares at a total cost of HKD 6.2941 million [1] - The buyback price ranges from HKD 14.74 to HKD 15.04 per share [1] Financial Implications - The total expenditure for the buyback reflects a strategic move to enhance shareholder value [1]